Cha Kwang-ryul Cha Hospital and Cha BioGroup Director of Global Research Institute informs K-cell excellence in international studies one after another
Nov 17, 2025
Cha Kwang-ryul Tea Hospital/Cha BioThe head of the Group Global Research Institute gave a special lecture on the theme of 'Nanson Aging and K-Cell' at the Trans-Pacific Reproductive Medicine Society (PSRM) held in Malaysia on the 8th and the National University of Singapore (NUS)-CHA Symposium held in Singapore on the 10th, receiving great response from the participants.
At this meeting, the head of the research institute, Cha Hospital and Cha Bio, will be the head of ChaThe group researchers explained the current status of cell therapy research by explaining the case of securing meaningful results such as recovery of ovulation cycle, increased estrogen secretion, and reduction of follicle cell death in naturally aged mice as a result of conducting an ovarian recovery study using MPC (intermediate leaf stem cells) made from embryonic stem cells, placenta, and excised blood.
"K-cells, which Korea has patents and technologies, are more stable than embryonic stem cells and induced pluripotent differentiated stem cells, iPCSs, which the United States and Japan have patents and technologies," Cha explained. He said "Induced pluripotent stem cells (iPS cells) in Japan, which are currently being actively studied, are likely to be unstable by returning grown-up cells to the state of embryonic stem cells, which are primitive cells.". He also emphasized that `K-cells made by Cha Hospital have high safety and genetic stability because they obtain embryonic stem cells directly from eggs.' "The Cha Hospital has more than 200 patents for somatic cell cloning stem cells in Korea, the 10th largest in the world." "There is a bank that differentiates this into cells that meet global clinical standards, so various joint studies are possible" he said." In addition, it attracted attention by explaining fetal tissue cells donated by ectopic pregnancy, which are known to be the most effective among adult stem cells.
Cha Kwang-ryul, director of the institute, said, "The reason why such research was possible at a car hospital was because it started with the study of eggs. "Research that began in reproductive medicine is moving on to cell therapy that will change the paradigm of human treatment."Growth medicine research also needs to be coordinated and studied in many ways from that perspective." he offered his opinion. He also said "Cha Hospital, Cha Bio."The group has a base base for cell therapy research and clinical practice in 96 centers in 7 countries, has CDMOs that can produce cell therapy in the United States, Japan, and Korea, and has all ecosystems in industry-academic cooperation, so it is also open to the development of treatments through joint cooperation," he added.
Chung Yap Seng, president of the Medical School at the National University of Singapore, said "The presentation of Cha Kwang-ryul, director of the research institute, on cell therapy research was quite encouraging and interesting. I think stem cells are a big leap forward that can transform reproductive medicine"We look forward to continuing cooperation based on each other's scientific and clinical strengths in the future." he said.
Maurizah Mohammad Zain, president of Malaysia who hosted the Asia-Pacific Reproductive Medicine Association (PSRM), said, "Cha Kwang-ryul, head of the Global Research Institute, is a pioneer in the Asia-Pacific fertility reproductive medicine field," adding, "The conference, which was organized by scholars from Australia and Japan, led by Cha Kwang-ryul, head of the Asia-Pacific Reproductive Medicine Institute in 1998, allowed Asian Reproductive Medicine, which was staying on the periphery, to grow globally.", he explained.
Meanwhile, Cha Kwang-ryul, head of the research institute, plans to continue promotional activities to promote the excellence of K cells and Korea's potential for cell therapy at domestic and overseas conferences in order to broaden the understanding and base of K cells.
At this meeting, the head of the research institute, Cha Hospital and Cha Bio, will be the head of ChaThe group researchers explained the current status of cell therapy research by explaining the case of securing meaningful results such as recovery of ovulation cycle, increased estrogen secretion, and reduction of follicle cell death in naturally aged mice as a result of conducting an ovarian recovery study using MPC (intermediate leaf stem cells) made from embryonic stem cells, placenta, and excised blood.
"K-cells, which Korea has patents and technologies, are more stable than embryonic stem cells and induced pluripotent differentiated stem cells, iPCSs, which the United States and Japan have patents and technologies," Cha explained. He said "Induced pluripotent stem cells (iPS cells) in Japan, which are currently being actively studied, are likely to be unstable by returning grown-up cells to the state of embryonic stem cells, which are primitive cells.". He also emphasized that `K-cells made by Cha Hospital have high safety and genetic stability because they obtain embryonic stem cells directly from eggs.' "The Cha Hospital has more than 200 patents for somatic cell cloning stem cells in Korea, the 10th largest in the world." "There is a bank that differentiates this into cells that meet global clinical standards, so various joint studies are possible" he said." In addition, it attracted attention by explaining fetal tissue cells donated by ectopic pregnancy, which are known to be the most effective among adult stem cells.
Cha Kwang-ryul, director of the institute, said, "The reason why such research was possible at a car hospital was because it started with the study of eggs. "Research that began in reproductive medicine is moving on to cell therapy that will change the paradigm of human treatment."Growth medicine research also needs to be coordinated and studied in many ways from that perspective." he offered his opinion. He also said "Cha Hospital, Cha Bio."The group has a base base for cell therapy research and clinical practice in 96 centers in 7 countries, has CDMOs that can produce cell therapy in the United States, Japan, and Korea, and has all ecosystems in industry-academic cooperation, so it is also open to the development of treatments through joint cooperation," he added.
Chung Yap Seng, president of the Medical School at the National University of Singapore, said "The presentation of Cha Kwang-ryul, director of the research institute, on cell therapy research was quite encouraging and interesting. I think stem cells are a big leap forward that can transform reproductive medicine"We look forward to continuing cooperation based on each other's scientific and clinical strengths in the future." he said.
Maurizah Mohammad Zain, president of Malaysia who hosted the Asia-Pacific Reproductive Medicine Association (PSRM), said, "Cha Kwang-ryul, head of the Global Research Institute, is a pioneer in the Asia-Pacific fertility reproductive medicine field," adding, "The conference, which was organized by scholars from Australia and Japan, led by Cha Kwang-ryul, head of the Asia-Pacific Reproductive Medicine Institute in 1998, allowed Asian Reproductive Medicine, which was staying on the periphery, to grow globally.", he explained.
Meanwhile, Cha Kwang-ryul, head of the research institute, plans to continue promotional activities to promote the excellence of K cells and Korea's potential for cell therapy at domestic and overseas conferences in order to broaden the understanding and base of K cells.
|
This article was translated by Naver AI translator.
